Halozyme Therapeutics total liabilities and share holders equity for the quarter ending September 30, 2024 was $2.118B, a 11.91% increase year-over-year.
Halozyme Therapeutics total liabilities and share holders equity for 2023 was $1.733B, a 5.88% decline from 2022.
Halozyme Therapeutics total liabilities and share holders equity for 2022 was $1.842B, a 66.74% increase from 2021.
Halozyme Therapeutics total liabilities and share holders equity for 2021 was $1.104B, a 90.44% increase from 2020.
Halozyme Therapeutics Total Liabilities and Share Holders Equity 2010-2024 | HALO